



## New Insights into Esophageal Cancer Chemotherapy

Guest Editor:

**Dr. Kenneth Meredith**  
Department of Surgical  
Oncology, Sarasota Memorial  
Hospital, Sarasota, FL, USA

Deadline for manuscript  
submissions:  
**closed (30 September 2024)**

### Message from the Guest Editor

Dear Colleagues,

Recent advancements in esophageal cancer chemotherapy have provided valuable insights into more effective treatment strategies. Researchers have uncovered novel drug combinations that target specific molecular pathways involved in esophageal cancer progression. These approaches aim to enhance the efficacy of chemotherapy while minimizing adverse side effects. Additionally, personalized treatment plans based on a patient's genetic profile are becoming increasingly common, allowing for tailored therapies that improve overall outcomes. These innovative insights offer hope for more successful and less invasive management of esophageal cancer, potentially leading to improved patient survival rates and a better quality of life during treatment.

Dr. Kenneth Meredith  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)